Chirag B Patel, MD
Neurology · Houston
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Physicians Referral Service · 2,728 clinicians in this group
Hospitals listed: University of Texas M D Anderson Cancer Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Patel’s office at (713) 792-2121 to ask if they take your plan before you enroll.
California Medical Board record
Licence A131532 · Delinquent
Licence status: Delinquent · since 2014 · expires 2022-05-31 · University of Texas Medical School at Houston.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$13,537
Medicare paid this office $13,537 for 75 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $3,923 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,152 | $93 |
| New patient visit (60+ min) | 20 | $2,888 | $144 |
| Long return visit (40+ min) | 11 | $1,834 | $115 |
Who their Medicare patients are
75 Original Medicare patients in 2024. Average age 72 · Women 43% · Health risk score 2.37. Sicker patients than 9 in 10 peers; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Cancer 45% · Stroke 45% · Diabetes 36% · Coronary heart disease 35% · COPD 33% · Chronic kidney disease 32% · Depression 29% · Dementia 28% · Heart failure 24% · Atrial fibrillation 24%.
The office billed $61,053, Medicare allowed $17,114 and paid $13,537; for 126 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 75 | 126 | 72 | 2.37 | $61,053 | $13,537 |
| 2023 | 81 | 154 | 70 | 2.86 | $69,511 | $16,665 |
| 2022 | 64 | 134 | 72 | 2.95 | $51,455 | $13,916 |
| 2021 | 54 | 169 | 71 | 2.69 | $116,070 | $20,911 |
| 2020 | 51 | 152 | 71 | 2.42 | $83,096 | $16,841 |
| 2019 | 37 | 71 | 68 | 2.30 | $11,890 | $7,606 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $5,133 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $4,978 | $135 |
| New patient visit (60+ min) | 26 | $3,741 | $144 |
2022: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,481 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $4,438 | $81 |
| New patient visit (60+ min) | 16 | $2,420 | $151 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $315 | $26 |
2021: 2 services
| Long return visit (40+ min) | 49 | $17,897 | $135 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $593 | $30 |
2020: 2 services
| Long return visit (40+ min) | 35 | $10,562 | $102 |
| New patient visit (60+ min) | 15 | $2,329 | $155 |
2019: 2 services
| Long return visit (40+ min) | 20 | $4,079 | $99 |
| Long return visit (40+ min) | 13 | $1,791 | $99 |
Medicaid work
$873 in 2021
Medicaid paid $873 for 14 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 14 | $873 |
| 2021 | 14 | 1 | 12 | $873 |
Money from drug and device companies
$71 in 2025
| 2025 | 2 | 2 | None | $71 |
| 2024 | 1 | 1 | None | $312 |
| 2023 | 4 | 12 | $7,800 | $8,256 |
| 2022 | 2 | 6 | None | $1,036 |
| 2021 | 2 | 4 | $3,000 | $3,223 |
| 2020 | 1 | 1 | None | $21 |
| 2019 | 1 | 8 | None | $739 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mallinckrodt Hospital Products | Acthar | $37 | 1 payment
|
| CSL Behring | Hizentra | $33 | 1 payment
|
See all 2 published payments
| Mallinckrodt Hospital Products | Meals · 2025-08-23 | Acthar | $37 |
| CSL Behring | Meals · 2025-04-22 | Hizentra | $33 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $312
| Intuitive Surgical | Da Vinci Surgical System | $312 | 1 payment
|
2023: $8,256
| Abbvie | Qulipta | $8,050 | 5 payments
|
| Novocure | Optune | $110 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $71 | 5 payments
|
| TG Therapeutics | Briumvi | $24 | 1 payment
|
2022: $1,036
| Novocure | Optune | $1,022 | 5 payments
|
| Teva Pharmaceuticals USA | Ajovy | $14 | 1 payment
|
2021: $3,223
| Novocure | Optune | $3,198 | 3 payments
|
| AbbVie | Ubrelvy | $25 | 1 payment
|
2020: $21
| Allergan | Ubrelvy | $21 | 1 payment
|
2019: $739
| Novocure | Oncology | $739 | 8 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novocure Inc. · Ef-41/?Keynote D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (Ef-41) · 2025 | Their institution | $215,280 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1467727792
- Licence
- CA A131532California A131532: Delinquent · expires 2022-05-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Student in a training program (390200000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-03-20
- NPI last updated
- 2019-06-26
This is when the NPI record was last certified, not a medical board exam.